Skip to Main Content

Paper Details

Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy.
Br J Cancer
0
2022
Author NameAffiliation
Oscar M RuedaUniversity of Cambridge
Carlos CaldasCancer Research UK Cambridge Institute, University of Cambridge
Carlos CaldasUniversity of Cambridge
Carlos CaldasCambridge Experimental Cancer Medicine Centre (ECMC) and NIHR Cambridge Biomedical Research Centre, University of Cambridge and Cambridge University Hospitals NHS Foundation Trust
Louis VermeulenCenter for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology and Metabolism, Amsterdam University Medical Centers
Louis VermeulenOncode Institute
  • 1 - 6

Datasets